%0 DATA
%A Romain, Gallet
%A Geoffrey, de Couto
%A Eli, Simsolo
%A Jackelyn, Valle
%A Baiming, Sun
%A Weixin, Liu
%A Eleni, Tseliou
%A Michael R., Zile
%A Eduardo, Marbán
%D 2019
%T Figure 1: Rat Model of HFpEF: Phenotype and Responsiveness to Treatment With Cardiosphere-Derived Cells
%U https://multimedia.onlinejacc.org/articles/Figure_1_Rat_Model_of_HFpEF_Phenotype_and_Responsiveness_to_Treatment_With_Cardiosphere-Derived_Cells/8253827
%R 10.25407/JACBTS.8253827.v1
%2 https://multimedia.onlinejacc.org/ndownloader/files/15429947
%K animal models
%K cell therapy
%K diastolic function
%K heart failure with preserved ejection fraction
%X **(A)** Study design. **(B)** Cardiosphere-derived cell manufacturing protocol. **(C)** Representative images of transmitral flow by Doppler echocardiography at endpoint in control, placebo-treated, and cardiosphere-derived cell (CDC)–treated rats. **(D)** CDC treatment normalizes ratio of early to late ventricular filling velocity (E/A ratio) at 4 weeks, while the E/A ratio in placebo-treated rats remains depressed. Systolic function assessed by left ventricular ejection fraction (LVEF) **(E,F)** and by fractional area change (FAC) **(G,H)** is equivalent in all groups. Left ventricular end-diastolic and end-systolic volumes **(I)** are equivalent in all groups. **(J)** CDC treatment halts heart failure with preserved ejection fraction–related left atrial enlargement, while placebo does not. (Baseline and pre-treatment, n = 10 for control rats and n = 24 for placebo- and CDC-treated rats; 1 week post-treatment, n = 10 for control rats, n = 21 for placebo- and CDC-treated rats; at endpoint, n = 10 for control rats, n = 15 for placebo-treated rats, n = 18 for CDC-treated rats). *p < 0.05 versus placebo and CDC groups and †p < 0.05 versus placebo, both by analysis of variance. LAV = left atrial volume; LVV = left ventricular volume; PBS = phosphate-buffered saline; ttt = treatment.